InsidersTradesSigma
Follow the HANGER, INC. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, HANGER, INC. has recorded 92 insider filings. The latest transaction was filed on 4 October 2022 (Disposition). Among the most active insiders: Kiraly Thomas E. The full history is free.
92
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€42m
26 ops.
Sell Volume
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 October 2022
Declarations92 total
31,384 shares@ US$18.7584.7% of flowCommon StockSEC:0001567619-22-018164:0
107,009 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018184:0
40,300 shares@ US$18.7593.3% of flowCommon StockSEC:0001567619-22-018170:0
43,561 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018179:0
76,414 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018176:0
20,594 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018186:0
33,745 shares@ US$18.7594.3% of flowCommon StockSEC:0001567619-22-018168:0
62,026 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018197:0
233,163 shares@ US$18.7576.5% of flowCommon StockSEC:0001567619-22-018162:0
67,851 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018189:0
5,760 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018160:0
78,135 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018195:0
11,325 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018158:0
70,837 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018191:0
132,371 shares@ US$18.7561.1% of flowCommon StockSEC:0001567619-22-018166:0
102,641 shares@ US$18.7564.4% of flowCommon StockSEC:0001567619-22-018156:0
39,213 shares@ US$18.7594.0% of flowCommon StockSEC:0001567619-22-018154:0
43,561 shares@ US$18.75100.0% of flowCommon StockSEC:0001567619-22-018181:0
723,149 shares@ US$18.7569.5% of flowCommon StockSEC:0001567619-22-018172:1
206,845 shares@ US$18.7519.9% of flowCommon StockSEC:0001567619-22-018172:2
10,597 shares0Common StockSEC:0001567619-22-018172:0
2,442 shares0Common StockSEC:0001567619-22-018174:0
1,031 shares@ US$14.281.8% of flowCommon StockSEC:0001567619-22-014124:0
990 shares@ US$14.5112.6% of flowCommon StockSEC:0001567619-22-013260:0
9,911 shares0Common StockSEC:0001567619-22-012298:0
25 of 92 declarations
关于 HANGER, INC.
Hanger, Inc.（股票代码HGR）是一家在美国纽约证券交易所/纳斯达克上市的公司，在美国运营，活跃于矫形器和假肢（O&P）护理市场。其核心业务是为面临肢体缺失、肢体差异以及其他与行动能力相关或骨科支持需求的患者设计、制造、分销和提供医疗解决方案。该公司以其患者护理网络Hanger Clinic以及连接临床护理、产品开发、制造、分销和患者支持的综合O&P生态系统而闻名。（[news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai)) Hanger的历史可追溯到1861年，当时詹姆斯·爱德华·汉格（James Edward Hanger）在美国内战中失去一条腿后，开发出一种早期的假肢解决方案，并创立了这家公司。这一起源赋予了公司在行动能力护理领域独特的悠久历史。随着时间的推移，Hanger从一家手工假肢企业发展成为一个规模化的临床和制造平台。公司总部位于德克萨斯州奥斯汀，巩固了其在美国的基地以及获取医疗保健和技术人才的优势。（[news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai)) 运营上，Hanger分为两个主要部门：患者护理和产品与服务。患者护理包括Hanger Clinic网络，该网络提供个性化的矫形器和假肢治疗以及定制的患者解决方案。产品与服务涵盖O&P组件、矫形器、假肢、儿科解决方案和相关设备的制造和分销。管理层强调以结果为导向的模型，这意味着公司专注于可衡量的临床结果、功能改善和长期患者价值，而不仅仅是产品销量。（[news.hanger.com](https://news.hanger.com/about-us/?utm_source=openai)) 从竞争角度来看，Hanger是美国O&P市场中知名的规模化参与者之一。其优势包括全国范围的覆盖、综合护理和产品模式，以及对临床研究和教育的持续投资。公司还强调其专业的培训基础设施，包括自1996年以来已培训950多名住院医师的全国O&P住院医师项目，以及一个致力于研究和循证护理的机构。（[corporate.hanger.com](https://corporate.hanger.com/news/2026/hanger-institute-for-clinical-research-and-education-releases-2025-2026-annual-report-highlighting-landmark-advances-in-orthotic-and-prosthetic-care/?utm_source=openai)) 从地理上看，Hanger的业务范围绝大部分在国内，根据公司最近的通讯，全国拥有925多个患者护理点，以及位于美国的制造和分销业务。一个值得注意的运营发展是2024年在加利福尼亚州弗雷斯诺开设了西海岸分销中心，该中心支持全国范围内的O&P产品配送。（[corporate.hanger.com](https://corporate.hanger.com/news/2025/hanger-clinic-enters-clinical-services-agreement-for-orthotic-and-prosthetic-care-with-premier-inc/?utm_source=openai)) 最近的战略和产品新闻突显了公司对创新的关注。2025年，Hanger宣布即将收购Point Designs，一家专注于部分手部假肢和增材制造的公司。公司的产品组合也通过Surestep的3D打印颅骨重塑矫形器发布而出现了新的产品活动。2026年，Hanger Institute发布了其2025-2026年度报告，强调了临床研究、人工智能辅助决策和循证O&P护理方面的进展。总而言之，这些发展表明公司正在将自己定位为专业医疗保健领域中临床差异化的领导者。（[news.hanger.com](https://news.hanger.com/press-releases/press-release-details/2025/Hanger-Announces-Impending-Acquisition-of-Point-Designs/default.aspx?utm_source=openai))
